Clinical Trial

Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk

Study acronym: Locus-Tau
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-28; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2026-07-15
Trial Details
NCT Number NCT07007208
Lead Sponsor University Hospital, Toulouse
Conditions Alzheimer Disease
Enrollment 100 participants
Start Date 2026-02-02
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17